This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): pegfilgrastim, Neupopeg, Neupogen SD, SD/01, KRN125, G-Lasta (Japan), Ristempa (EU)
Description: Neulasta is a pegylated formulation of Amgen's Neupogen in which the recombinant protein G-CSF is attached to polyethylene-glycol (PEG). Pegylated proteins have increased plasma half-lives. Therefore, patients require less frequent injections of Neulasta compared to Neupogen.
Both drugs restore levels of circulating neutrophils, a type of white blood cell important in fighting infections. Chemotherapy, radiation, cancer itself, HIV, and various, especially chronic, diseases may contribute to patients' experiencing neutropenia. Neulasta was approved for use for cancer patients whose ability to fight infection has been weakened by chemotherapy.
Deal Structure: Revenue splits for this drug are BioMedTracker estimates.
Roche and Amgen
Neupogen is marketed by Amgen in the U.S. and is co-marked with Roche in Europe. In May 2002, Amgen bought back some of the rights to Neupogen and Neulasta from Roche.
In October 2013, Amgen announced that it has entered into a definitive agreement with Roche to acquire Roche's rights to filgrastim and pegfilgrastim in approximately 100 markets, effective Jan. 1, 2014. Amgen will begin distributing and selling product as soon as practical in countries where the Company has an existing commercial presence. In countries where Amgen does not have a presence, Roche or its distributors will continue to sell and distribute the products for an interim transition period. Kyowa Hakko Kirin Co., Ltd. of Japan will continue to retain product rights and market filgrastim and pegfilgrastim in some selected Asian territories, including China and Japan.
Amgen and Nektar
Amgen licensed the...See full deal structure in Biomedtracker
Partners: Roche Holding AG Nektar Therapeutics Kyowa Hakko Kirin Co., Ltd. DRI Capital Inc.
Pink Sheet Fulphila Reviewers
Pink Sheet Fulphila Clinical Development Timeline
Additional information available to subscribers only: